Table 3.
Response evaluation and treatment outcomes stratified by first-line treatment strategy.
| Chemotherapy (n = 222) | Endocrine therapy (n = 80) | Chemotherapy-endocrine therapy (n = 149) | P Valuea | |
|---|---|---|---|---|
| Best response | <0.001 | |||
| Complete response | 8 (3.6%) | 6 (7.5%) | 9 (6.0%) | |
| Partial response | 72 (32.4%) | 9 (11.3%) | 71 (47.7%) | |
| Stable disease | 53 (23.9%) | 36 (45.0%) | 53 (35.6%) | |
| Progressive disease | 49 (22.1%) | 13 (16.3%) | 1 (0.7%) | |
| Objective response rate | 36.0% | 18.8% | 53.7% | <0.001 |
| Progression-free survival median (95% CI) | 7.1 (5.9–8.3) | 11.7 (9.7–13.6) | 18.9 (16.2–21.7) | <0.001 |
| Overall survival median (95% CI) | 43.9 (39.0–48.8) | 53.5 (40.4–66.6) | 75.0 (57.3–92.7) | <0.001 |
a
Bold values indicate statistically significant results.